This study is a 12-week randomized-controlled clinical trial. It will be planned to conduct in a total of 120 male and female subjects from the Department of Psychiatry at Kaohsiung Chang Gung Memorial Hospital. Eligible subjects will be psychiatric patients, aged between 20-65 years old, who have psychiatric diagnosis of schizophrenia and fulfill the inclusion and exclusion criteria. The intervention with aerobic walking programs will be initiated after randomization for patients who continue their usual treatment. Subjects will be enrolled for 12 weeks aerobic walking treatment and randomly assigned to (1) treatment-as-usual, (2) treatment-as-usual plus aerobic walking. We will measure the treatment response to clarify the effect of aerobic walking in patients with schizophrenia. This study is being performed to investigate the possibly beneficial effects of aerobic walking on cognitive function and energy metabolites in schizophrenia.
This 12-week randomized-controlled clinical trial will be planned to conduct in a total of 120 male and female subjects from the Department of Psychiatry at Kaohsiung Chang Gung Memorial Hospital. Eligible subjects will be psychiatric patients, aged between 20-65 years old, who have psychiatric diagnosis of schizophrenia and fulfill the inclusion and exclusion criteria. The intervention with aerobic walking programs will be initiated after randomization for patients who continue their usual treatment. Subjects will be enrolled for 12 weeks aerobic walking treatment and randomly assigned to (1) treatment-as-usual, (2) treatment-as-usual plus aerobic walking. The wearable watch will be used during the participants join the walking programs. We will measure the treatment response to investigate the effect of aerobic walking in patients with schizophrenia. This study is being performed to investigate the possibly beneficial effects of aerobic walking on cognitive function in schizophrenia.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
85
aerobic walking
Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan
cognitive function change
cognitive function change assessed by Brief Assessment of Cognition in Schizophrenia
Time frame: week 12
treatment change assessed by serum levels of energy metabolites (e.g., β-hydroxybutyrate)
change assessment
Time frame: week 12
treatment change assessed by the Positive and Negative Syndrome Scale
minimum value 30, maximum value 210; higher scores mean a worse outcome
Time frame: week 12
treatment change assessed by peripheral blood metabolic profiles (e.g., plasma cholesterol level)
change assessment
Time frame: week 12
treatment change assessed by metabolic profiles (e.g., body weight in kilograms)
change assessment
Time frame: week 6, week 12
treatment change assessed by serum levels of inflammatory cytokines (e.g., IL-8)
change assessment
Time frame: week 12
treatment change assessed by 6-minute walk test
change assessment
Time frame: week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.